By now, if you hear the word "vaccine", you probably think COVID-19. But there are obviously many other vaccines in use and under development, and there's good news about another one, a malaria vaccine.
The researchers report a vaccine efficacy of 77% in the higher-dose adjuvant group, and 71% in the lower dose adjuvant group, over 12 months of follow-up, with no serious adverse events related to the vaccine noted.
Following these results, the Phase IIb trial, which was funded by the EDCTP2 programme supported by the European Union (grant number RIA2016V-1649-MMVC), was extended with a booster vaccination administered prior to the next malaria season one year later.
This is big news. Malaria is a scourge that kills more than 400,000 people a year, and the malaria parasite has been very good at evading previous attempts to create a vaccine.
No comments:
Post a Comment